Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Uptravi (selexipag) - Important Safety Information from Actelion Pharmaceuitcals UK Ltd as approved by the HPRA
Notice type:
3rd Party Publications
Date:
16/06/2017
Problem Or Issue:
Important Safety Information communication from Actelion Pharmaceuticals UK Ltd: Uptravi (selexipag) - concomitant use with strong CYP2C8 inhibitors (e.g. gemfibrozil) now contraindicated.
Important Safety Information - Uptravi (selexipag)
« Back
Date Printed: 19/04/2024